Ionis Pharmaceuticals concludes REVEAL study pivotal cohort enrolment

Ionis Pharmaceuticals has concluded enrolment in the pivotal cohort of its Phase III REVEAL study of obudanersen as an investigational RNA-targeted medicine for AS. The company expects top line data from the study in the second half of 2027. The pivotal cohort enrolled 136 participants aged two to below 18 years, all with AS and genetically confirmed UBE3A mutation. Credit: Shidlovski / Shutterstock.com. Ionis Pharmaceuticals has concluded enrolment in the pivotal cohort (Cohort 1) of its Phase III REVEAL study of obudanersen (ION582) as an investigational ribonucleic acid (RNA)-targeted medicine for Angelman syndrome (AS). The randomised, global, controlled, double-blind trial…

Source: Clinical Trials Arena